Latest Conference

Ellie J C Goldstein, MD, stresses the importance of improving transition of care with better communication.

SCY-078 has demonstrated potent activity against Aspergillus and Candida, recent data suggests.

The American Society for Microbiology’s (ASM) annual meeting, held June 7-11, 2018, in Atlanta, Georgia, featured results of numerous studies on and advancements being made in infectious diseases. Here are 5 key takeaways from the meeting.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Single-dose vaccines delivered via a new technology platform may offer full protection against Zika, Lassa fever, and Ebola.

IMI/REL was effective against isolates from the United States and Europe.

Researchers find that Treg cells could be vital in protecting infants in the womb from mother-to-child HIV transmission.

Researchers from the Chang-Gung Memorial Hospital find that half of influenza cases in patients admitted to the ICU received a false-negative rapid influenza antigen test.

In the past 17 years, the number of hospitalizations due to cUTIs has risen by 50%.

Emerging Candida species prove capable of virulent spread in health care facilities, leading to outbreaks.

Pooled analyses of 2 phase 3 trials have conclusively established the safety and effectiveness of iclaprim compared to vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI).

The President’s Forum at this year’s ASM Microbe meeting opened the eyes of many in the audience to the capacity of microorganisms to evolve.

The incidence of IE was lower in patients having a lower white blood cell count and lower numbers of platelets.

The results of a new study have revealed that carbapenem resistance conferred by plasmids can be transferred among unrelated bacteria in the health care setting.

Xingmin Sun, PhD, shares current progress on developing a vaccine for Clostridium difficile infection.

Xingmin Sun, PhD, discusses aspects that need to be considered before developing a vaccine for Clostridium difficile.

The pooled results have hammered home the promise of eravacycline for the treatment of patients with cIAIs who are colonized by drug-resistant bacteria.

Anne Schuchat, MD, provides some history and insights on CDC’s role in safeguarding public health when the microbial world collides with the human world.

An extremely virulent (hypermucoviscous) strain of Klebsiella pneumoniae that is resistant to carbapenem and colistin has been isolated for the first time from a patient in the United States.

Sixty-nine out of the 70 colistin-resistant isolates had either mcr-1 and/or mcr-3 genes.

Chelsea Drennan, PharmD(c) explains why hospital length-of-stay might be shorter in patients who are on a fluoroquinolone versus a beta-lactam.

Empiric use of fluoroquinolones looks to be an alternate option for the treatment of gram-negative bloodstream infections when risk factors for antimicrobial resistance are not present.

Researchers from Vanderbilt University Medical Center determine the metabolic pathway that S aureus uses to survive in bones.

A prospective examination of over 2600 patients has not revealed a difference in their outcome compared with patients who are non-neutropenic when it comes to bacteremia caused by Staphylococcus aureus.

The opening session of ASM Microbe 2018 cuts a broad swath through the science of microbiology.

The drug met its primary endpoint of noninferiority to vancomycin at both 48 to 72 hours after drug initiation and test of cure.

Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.

New software unveiled last month suggests hospitals could make patient-specific predictions of antibiotic susceptibility.

An outbreak of infections caused by the drug-resistant fungus, Candida auris, in one United Kingdom hospital has been linked to multi-use patient equipment.

Julia E. Szymczak, PhD, shares the results of her study which revealed that fear drives some clinicians to prescribe inappropriately.